Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 14;11(3):512.
doi: 10.3390/diagnostics11030512.

Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice

Celine Jacobs  1 , Lore Lapeire  1   2
Affiliations
Review

Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice

Celine Jacobs et al. Diagnostics (Basel). .

Abstract

Soft tissue sarcomas are a group of rare mesenchymal tumors with more than 70 subtypes described. Treatment of these subtypes in an advanced setting is mainly according to a one-size-fits-all strategy indicating a high unmet need of new and more targeted therapeutic options in order to optimize survival. The introduction of advanced molecular techniques in cancer has led to better diagnostics and identification of new therapeutic targets, leading to more personalized treatment and improved prognosis for several cancer types. In sarcoma, a likewise evolution is seen, albeit at a slower pace. This manuscript describes how in the past years advanced molecular profiling in soft tissue sarcomas was able to identify specific and often pathognomonic aberrations, deferring standard sarcoma treatment in favor of more targeted treatment from an oncologist's point of view.

Keywords: ALK; CDK4; KIT; MDM2; NR4A3; NTRK; PD-1; PDGFRA; molecular profiling; sarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Casali P., Abecassis N., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Brodowicz T., Broto J., et al. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018;29:iv51–iv67. doi: 10.1093/annonc/mdy096. - DOI - PubMed
    1. Vos M., Sleijfer S. EJC’s biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. Eur. J. Cancer. 2018;88:87–91. doi: 10.1016/j.ejca.2017.10.020. - DOI - PubMed
    1. Judson I., Verweij J., Gelderblom H., Hartmann J.T., Schöffski P., Blay J.-Y., Kerst J.M., Sufliarsky J., Whelan J., Hohenberger P., et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–423. doi: 10.1016/S1470-2045(14)70063-4. - DOI - PubMed
    1. Sheng J.Y., Movva S. Systemic Therapy for Advanced Soft Tissue Sarcoma. Surg. Clin. North. Am. 2016;96:1141–1156. doi: 10.1016/j.suc.2016.06.006. - DOI - PubMed
    1. Malone E.R., Oliva M., Sabatini P.J.B., Stockley T.L., Siu L.L. Molecular profiling for precision cancer therapies. Genome Med. 2020;12:1–19. doi: 10.1186/s13073-019-0703-1. - DOI - PMC - PubMed

LinkOut - more resources